An early study of fecal transplant to help slow early-stage motor neuron disease progression

A randomized clinical trial is looking at whether fecal microbiota transplantation (FMT) from healthy donors into adults with early-stage amyotrophic lateral sclerosis (ALS—one of the most common forms of motor neuron disease) can modulate the immune reaction during inflammation responses that characterize disease progression, and aims to investigate the relationship between specific gut bacteria and their action on immune system cells.
A randomized clinical trial is looking at whether fecal microbiota transplantation (FMT) from healthy donors into adults with early-stage amyotrophic lateral sclerosis (ALS—one of the most common forms of motor neuron disease) can modulate the immune reaction during inflammation responses that characterize disease progression, and aims to investigate the relationship between specific gut bacteria and their action on immune system cells.